Muhammad Zaeem Noman
Latest publications
Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer.
- Tumor Immunotherapy and Microenvironment
2021 Mar. Cancers.13(5):1165.
CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.
- Immuno-Pharmacology and Interactomics
- Tumor Immunotherapy and Microenvironment
- Allergy and Clinical Immunology
- Personalized Therapy Discovery
2021 Mar. Cancers.13(5):1054.
Targeting cytoprotective autophagy to enhance anticancer therapies.
- Tumor Immunotherapy and Microenvironment
2021 Feb. Front Oncol.11:626309.
Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.
- Tumor Immunotherapy and Microenvironment
2020 Nov. Autophagy.(11):2110-2111. Epub 2020 Sep 5.
The 'Holy Grail' in immuno-oncology: AC BioScience SA is aiming to potentiate anti-PD-1 therapy efficacy through tumor cell conditioning strategy.
- Tumor Immunotherapy and Microenvironment
2020 Oct. Chimia.74(10):771-775.
Firing up the cold tumors by targeting Vps34.
- Tumor Immunotherapy and Microenvironment
2020 Aug. OncoImmunology.9(1):1809936.
The emerging impact of autophagy on the antitumor immune response. In Autophagy in immune response: Impact on cancer immunotherapy. 1st ed. (Book Chapter)
- Tumor Immunotherapy and Microenvironment
2020 May. Chouaib S, ed. London: Academic Press, 2020. p.109-117. (Sensitizing Agent-Canc Resistant-Cell Mediated Immtherap, Vol.1). ISBN 978-0-12-819609-0.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
- Tumor Immunotherapy and Microenvironment
2020 May. Sci Adv.6(18):eaax7881.
Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges.
- Tumor Immunotherapy and Microenvironment
2019 Sep. Cells.8(9).
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.
- Tumor Immunotherapy and Microenvironment
2019 Aug. Cancer Lett.458:13-20. Epub 2019 May 25.
Driving cytotoxic natural killer cells into melanoma: If CCL5 plays the music, autophagy calls the shots.
- Tumor Immunotherapy and Microenvironment
- Immuno-Pharmacology and Interactomics
- Allergy and Clinical Immunology
2018 Sep. Crit Rev Oncog.23(5-6):321-332.
Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
2018 Apr. OncoImmunology.7(8):e1452583.
CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.
- Tumor Immunotherapy and Microenvironment
- Computational Biomedicine
2018 Feb. OncoImmunology.7(4):e1345415.
Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
- Platform National Cytometry
2017 Oct. Proc Natl Acad Sci U S A.114(44):E9271-E9279. Epub 2017 Oct 16.
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.
- Tumor Immunotherapy and Microenvironment
2017 Jan. OncoImmunology.6(1):e1263412.
Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity.
- Tumor Immunotherapy and Microenvironment
2017 Jan. OncoImmunology.6(2):e1271858.
Hijacker of the antitumor immune response: autophagy is showing its worst facet.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
2016 Nov. Front Oncol.6(246):246.
The multifaceted role of autophagy in tumor evasion from immune surveillance.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
2016 Apr. Oncotarget.7(14):17591-607.